MORRIS PLAINS, N.J., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that nine abstracts on its product candidates have been accepted for presentation at the 54th American Society of Hematology Annual Meeting, scheduled for December 8 – 11, 2012 in Atlanta, GA.
